Clinical Trial Update: PDE-4 Inhibitor Roflumilast and Polycystic Ovary Syndrome [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial investigating roflumilast (a PDE-4 inhibitor) for Polycystic Ovary Syndrome and obesity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Polycystic Ovary Syndrome

Drugs mentioned

• Roflumilast (roflumilast)

Snippet

Sponsor: University Medical Centre Ljubljana | Conditions: PCOS, Obesity | Phase 4 | Status: COMPLETED